Form 4: Pulse Biosciences CEO Thomas Barrett Receives Stock Options

Pulse Biosciences CEO Thomas Barrett was granted stock options for 1,400,000 shares on May 12, 2024, with vesting conditions tied to service and market capitalization milestones.

Summary

• Thomas Barrett, the President and CEO of Pulse Biosciences, Inc., received stock options on May 12, 2024.
• The options are for a total of 1,400,000 shares of common stock at an exercise price of $7.45.
• 700,000 shares vest in four equal annual installments starting on the first anniversary of the grant date, contingent upon continued service.
• The other 700,000 shares are subject to performance-based vesting criteria linked to Pulse Biosciences' market capitalization, requiring it to exceed $1 billion before any vesting occurs, also contingent upon continued service.
• The options expire on May 12, 2034.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the granting of stock options aligns the CEO's interests with shareholders and incentivizes growth. The performance-based vesting adds a layer of optimism, but the high market capitalization target introduces some uncertainty.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
• The performance-based vesting criteria tied to market capitalization encourages the CEO to drive significant growth for Pulse Biosciences.

Risks

• The performance-based vesting criteria may not be met if Pulse Biosciences' market capitalization does not reach $1 billion.
• The CEO's departure before the vesting dates would result in the forfeiture of unvested options.

Future Outlook

The stock options are designed to incentivize long-term growth and value creation at Pulse Biosciences, with vesting tied to both continued service and the achievement of a significant market capitalization milestone.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent while aligning their interests with those of shareholders. The use of market capitalization-based vesting is a way to ensure that executives are focused on driving significant value creation.

Comparison to Industry Standards

• Many biotech companies use stock options as part of their executive compensation packages.
• Companies like CRISPR Therapeutics and Editas Medicine also use a mix of time-based and performance-based vesting criteria for their executive stock options.
• The $1 billion market capitalization target is a significant milestone, reflecting a desire for substantial growth.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
• Employees may be motivated by the potential for company growth and success tied to the market capitalization target.

Key Dates